Company Overview and News
The U.S. Energy Department's weekly inventory release showed a natural gas storage injection that fell in line with market expectations. Meanwhile, natural gas prices rallied to their highest levels since January as inventories remain significantly below their five-year average ahead of the upcoming winter.
ECR CKRGZ CNX.WI CHKVP CRK RRL RRS CHKDH CHKVZ RGRLF CHKDG CHKWZ RRC CHKDJ CHKDP RGRYY CHK CHK.WI GPOR
Larger and more financially healthy E&P companies are grouped together for analysis purposes in this "Tier One Producer" or "TOP Club"
CRC GDPMQ CHKVP PSX CRK QEP CHKVZ CRZO GDAOQ EGC EXXIQ SNZYP GDRRQ AMPY TALO SRCI EEXXQ BCEI RRS JONE WPX ESTE EXXI GDP CHK SGY TTEN MPOYQ SDRXP LINE SDRXQ APA HES DVN PVA EPE PIONF CHKDH CHKDG MCF CHKDJ ROSEU VNR CHKDP REI RSPP JNEEP AMR AMGP JAG ROSE LINEQ CKRGZ EVEP EOG RGRYY UPLMQ VNRCP PIO LNGG AR SWTF AM EXIXQ CHAP VNRBP SN XOG NBL WLL PDCE SM CTLR HKRCP SD RGRLF RRC DNR MPO VNRAP CLR GDPAN GDPAQ ECR CHPE UPL WPXP SDRPQ REN PE CXO RRL SCAZP AXAS COP AREX ECA SFY EVEPQ CDEV BRMR GDPM PVAYQ VNRR ECA SBOW CHKWZ GDUEQ SDOCQ GDANQ CHK.WI PVAC LPI WES HK HPR BRY
Laredo Petroleum is facing oil price related problems which will hurt its realizations that are forecasted to drop to 83% of WTI in Q3-2018 from well over 90% previously.
CHKVP PXD RDSB RDSA CHKDH CHKVZ CHKDG CHKDJ CHKDP CME RYDAF JAG CKRGZ RDS.B RDS.A CHKWZ 7018 CHK.WI CHK LPI RYDBF TRI OXY FANG
2018-10-12 investorplace - 5
In any market — bull or bear — investors can always find turnaround stocks to buy. Companies are no more perfect than the humans that comprise them, after all. Mergers go south. Poor management can decimate morale. Sometimes, the world changes — and it takes a few years for a business to catch up.
LOW JCP CHKVP UAA CHKVZ TTS BHC SHLD NKE KMI VSI KMR CVB GE FTD CBS.WD CMG GPRO MAT CHK VZ CPV BATRA FTR LSXMB HD FIT BATRK CPB LSXMA FND BATRR CHKDH CHKDG VZA CHKDJ VRX CHKDP FTRPR GRMN AAPL BATRB CBS VIA CKRGZ GEC FWONB CBS.A QRTEA M FLWS FWONA CHKWZ UA HAS CHK.WI KHC FWONK GNE LSXMK KMRFZ DHR
2018-10-08 zacks - 1
The U.S. Energy Department's weekly inventory release showed a bigger-than-expected increase in natural gas supplies. Despite the stockpile surge, natural gas prices rallied to their highest levels since January as inventories remain significantly below their five-year average ahead of the upcoming winter.
ECR CKRGZ FCN CNX.WI CHKVP CRK COG CVS CHKDH CHKVZ CHKDG CHKWZ CHKDJ CHKDP CHK CHK.WI GPOR
U.S. oil and gas M&A activity soared in the 3Q to $32 billion, a 250 percent increase from $9.1 billion in 2Q, according to new data from Drillinginfo, which provides software and data analytic services to the energy industry.
CKRGZ BLT CHKVP BHPBF CHKDH CHKVZ CHKDG CHKWZ CHKDJ CHKDP BHP CHK.WI CHK EGN BBL BHP BHPLF
2018-10-04 247wallst - 3
Stocks traded lower early Thursday after having hit all-time highs this week on the heels of a North America trade pact and after comments by Federal Reserve Chair Powell about the strength of the economy. The 10-year Treasury yield is now up to 3.20% and the 30-year Treasury yield is 3.36%, and now the 3% prior resistance may be support.
CHKVP CHKDH CHKVZ CHKDG CHKDJ CMQMY CHKDP MS TEAM EA CKRGZ IAC CMI CMG CHKWZ ALLY CLDR PEP CHK CHK.WI TRI SBUX HPQ
2018-10-03 sec.gov - 3
Document UNITED STATES
2018-10-03 investorplace - 7
Everybody loves a deal when it comes to investing. It’s why there are a lot of articles written about stocks under $10 and the reasons you should buy them. This article isn’t one of those.
NIO VIPS CKRGZ GE F CHKVP CHKDH CHKVZ ATVI CHKDG CHKWZ SHLD ZNGA GRPN BABA CHKDJ CHKDP CHK CHK.WI TSLA SHLDW SNAP
Chesapeake Energy (NYSE:CHK) has become the “Flying Dutchman” of the oilpatch, wandering from strike to strike, never able to reach the safe harbor of profit. CHK stock is down more than 14% in the past three months, compared to the S&P 500 index‘s almost 8% gain.
CHKDJ CKRGZ CHKDP CHK CHKVP CHK.WI CHKDH CHKVZ CHKDG CHKWZ
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET